Advertisement

Search Results

Advertisement



Your search for it matches 15588 pages

Showing 10451 - 10500


10 Bladder Cancer Projects Awarded Research Grants by Johns Hopkins Greenberg Bladder Cancer Institute

The Johns Hopkins Greenberg Bladder Cancer Institute is a collaborative initiative of the Johns Hopkins Kimmel Cancer Center, the Brady Urological Institute, the Bloomberg School of Public Health, and the School of Medicine. It aims to develop new clinical strategies for combating bladder cancer...

AACR CEO Margaret Foti, PhD, MD (hc), Honored With James Ewing Layperson’s Award From SSO

Margaret Foti, PhD, MD (hc), CEO of the American Association for Cancer Research (AACR), was recognized during the plenary session at the 69th Society of Surgical Oncology (SSO) Annual Cancer Symposium with the James Ewing Layperson’s Award for her dedication to the prevention and cure of cancer;...

A Political Activist Challenges the Drug Approval Process and the U.S. Government

The U.S. Food and Drug Administration’s (FDA’s) primary concern in the drug approval process is to ensure that the drug is safe and effective. For the past several decades, the advocacy groups have vociferously painted the agency as a stodgy bureaucracy that prevents desperate patients access to...

Things May Not Be What They Seem: Are Old Cancer Treatment Theories New Again?

The adage “you can’t judge a book by its cover,” is true, but authors still need to be aware of the importance of first impressions. The title of science writer Travis Christofferson’s book Tripping Over the Truth: The Return of the Metabolic Theory of Cancer Illuminates a New and Hopeful Path to ...

lung cancer

Crizotinib in ROS1-Positive Metastatic Non–Small Cell Lung Cancer

On March 11, 2016, crizotinib (Xalkori) was approved for treatment of patients with metastatic non–small cell lung cancer (NSCLC) with ROS1 rearrangement–positive tumors.1,2 A U.S. Food and Drug Administration–approved test for the detection of ROS1 rearrangements in NSCLC is not currently...

Lili Yang, PhD, Receives CIRM Funding to Investigate iNKT Modification and Transplantation

With new funding awarded by the California Institute for Regenerative Medicine (CIRM), Lili Yang, PhD, Assistant Professor in the Department of Microbiology, Immunology & Molecular Genetics and the Eli & Edythe Broad Center of Regenerative Medicine and Stem Cell Research (BSCRC) at the...

global cancer care

Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Israel

The ASCO Post is pleased to continue this special feature on the worldwide cancer burden. In this issue, we feature a close look at the cancer incidence and mortality rates in Israel. The aim of this special feature is to highlight the global cancer burden for various countries of the world. For...

pancreatic cancer

Phase Ib/II Study Reports High Response Rates Seen With Addition of Cisplatin to Regimen for Advanced Pancreatic Cancer

The oncology research team at HonorHealth Research Institute in Scottsdale, Arizona, is spearheading a phase Ib/II trial that is demonstrating promising results with a novel regimen in patients with advanced pancreatic cancer. “The patients we are treating have advanced adenocarcinoma of the...

Susan Block, MD, Honored With AAHPM Palliative Care Lifetime Achievement Award

Susan Block, MD, an institute physician in the Department of Psychosocial Oncology and Palliative Care at Dana-Farber Cancer Institute, a Harvard Medical School Professor, and Director of the Serious Illness Care Program at Ariadne Labs, received the Lifetime Achievement Award at the American...

Samuel Waxman Cancer Research Foundation Appoints Robert Hromas, MD, to Its Scientific Advisory Board

The Samuel Waxman Cancer Research Foundation (SWCRF) announced the addition of cancer researcher Robert Hromas, MD, Chair of Medicine at University of Florida Health, to its scientific advisory board (SAB). Dr. Hromas, who continues his position at the University of Florida Health, will join his...

health-care policy

Providing Perspective on Pressing Economic Issues Facing Cancer Care—Now and in the Future

CANCERSCAPE, the 2016 Annual Meeting of the Association of Community Cancer Centers (ACCC), provided a forum for about 300 attendees to gain insight into the complexities of oncology treatment, where “clinical advances, policy mandates, and value-based payment reform intersect.” Of particular...

ASCO Pledges to Advance Interoperability Among Health Information Systems

ASCO has joined members of the health-care community in pledging to the U.S. Department of Health and Human Services (HHS) to commit to principles that will advance interoperability among health information systems. A formal announcement of the initiative was delivered by HHS Secretary Sylvia M....

Understanding and Preparing for MACRA

The Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) was passed in April 2015, introducing comprehensive changes to how Medicare pays physicians for services. As the policies passed in MACRA are rolled out over the coming years, they will profoundly impact reimbursement and care...

Diversity Training Key to Increasing Cultural Competence Among Oncology Surgeons

A study in the Journal of Oncology Practice (JOP)1 measured the level of cultural competence among surgeons from six hospitals in the Puget Sound region of Washington State, home to a large population of American Indians and Alaskan Natives. According to the study, “Assessing Cultural Competence...

lymphoma

MicroRNA miR-181a Reduces NFκB Signaling in Diffuse Large B-Cell Lymphomas

A recent study by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine showed that a microRNA called miR-181a dampens signals from the cancer-driving NFκB protein pathway in diffuse large B-cell lymphoma (DLBCL). By reducing NFκB...

breast cancer

Pathologic Complete Response to Neoadjuvant Therapy Associated With Improved Outcomes in HER2-Positive Breast Cancer

Pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer was associated with a significantly better outcome vs non–pathologic complete response, in a patient-level meta-analysis reported by Broglio et al in JAMA Oncology. Response vs No Response The study included...

issues in oncology

New Commission on Cancer Standards Clarifies and Emphasizes Process, Quality, Data Reporting, and More

The 2016 edition of the Commission on Cancer’s accreditation standards manual clarifies and provides additional information in many areas and raises the bar for compliance in some, including psychosocial distress screening, survivorship care, data reporting, and activities in prevention and...

issues in oncology

Outcome Measures in Quality and Identifying High-Quality Practice

At this year’s ASCO Quality Care Symposium, Craig Earle, MD, MSc, of the Ontario Institute for Cancer Research, used Donabedian’s Triad—structure, process, and outcome—to set the stage for his presentation on the science of quality. “The theory behind Donabedian’s Triad is that structure...

issues in oncology
cost of care

Experts Consider What It Means to Improve Quality of Care in an Era of Increasing Reliance on Targeted Therapies

Precision medicine is judged according to different values across the multiple stakeholders involved in cancer care. At this year’s Quality Care Symposium, presenters from different sectors of oncology addressed a central question: How do we assess quality in the age of precision medicine?1,2 Right ...

breast cancer

A Business Professor and Husband Turns Breast Cancer Researcher

In more than 25 years of viewing posters at oncology meetings, I’ve met researchers from virtually all professional walks of life, but it was not until the 2016 Miami Breast Cancer Conference, that the author’s affiliation turned my head: It was a business school. “Utilizing Metastatic Tumor...

breast cancer

Metastatic Breast Cancer With Discordant Tumors: Small Study Reports Treatment by Primary Status May Improve Survival

In a small retrospective series, patients with metastatic breast cancer treated according to the receptor status of the primary tumor, not the metastatic one, had significantly longer median overall survival. The study was reported at the 2016 Miami Breast Cancer Conference by T. Allen Pannell, Jr, ...

breast cancer

Breast Cancer Vaccines Moving Forward at a Fast Clip

Vaccines for both secondary and primary prevention of breast cancer are showing potential in clinical trials, according to Elizabeth A. Mittendorf, MD, PhD, who is leading much of the vaccine research at the University of Texas MD Anderson Cancer Center, Houston. Vaccine platforms being explored...

gynecologic cancers

Expert Point of View: Kathleen Moore, MD

Session moderator Kathleen Moore, MD, Associate Professor of Obstetrics and Gynecology at the University of Oklahoma College of Medicine, Oklahoma City, said that while the response rates are “not incredibly high,” trabectedin offers another line of therapy where there previously was none. “I think ...

gynecologic cancers

Trabectedin Improves Progression-Free Survival in Uterine Leiomyosarcoma

In women with uterine leiomyosarcoma, trabectedin (Yondelis), a novel cytotoxic agent, significantly improved progression-free survival, compared with dacarbazine (4.2 vs 1.5 months, hazard ratio [HR] = 0.55, P < .001). According to the study’s authors, a lack of cumulative toxicity allows...

issues in oncology

Computer-Assisted Decision Support in Medical Oncology: We Need It Now

Today’s medical oncologist is increasingly challenged to stay current with the latest developments in cancer treatment. I have been fortunate to speak with many oncologists over the past quarter-century on how professional life has evolved since the 1990s. These conversations have left me with a...

prostate cancer

Throwing Out the Baby With the Bathwater: A Critical Appraisal of the USPSTF Recommendation Against Screening for Prostate Cancer

In 2012, the U.S. Preventive Services Task Force (USPSTF) issued a recommendation against routine screening for prostate cancer.1,2 The grade D recommendation was considered controversial at the time, and remains so now, because many stakeholders have weighed the same body of evidence and come to...

lung cancer

The POPLAR Trial: PD-L1 Blockade With Atezolizumab in Second- or Third-Line Non–Small Cell Lung Cancer

The randomized phase II ­POPLAR trial—reported by Fehrenbacher and colleagues and reviewed in this issue of The ASCO Post—is another key piece of information for the medical community regarding the value of immune checkpoint blockers in second/third-line treatment of patients with non–small cell...

survivorship

ENDO 2016: Engineered Ovary Implant Restores Fertility in Mice

Northwestern University scientists used a three-dimensional (3D) printer to create a prosthetic ovary—an implant that allowed mice that had their ovaries surgically removed to bear live young. The results were presented by Laronda et al on Saturday, April 2, at the Endocrine Society's Annual...

breast cancer

ENDO 2016: BPA Changes Fetal Development of the Mammary Gland, Can Raise Breast Cancer Risk

A new culture system that tests the role of chemical exposure on the developing mammary gland has found that bisphenol A (BPA) directly affects the mammary gland of mouse embryos. The study results, presented by Speroni et al Friday, April 1, at the Endocrine Society's Annual Meeting in Boston...

issues in oncology

TP53 Gene Variant S47 May Contribute to Increased Cancer Risk in People of African Descent

For years, clinical data have shown that African Americans have a higher death rate and shorter period of survival among patients with commonly diagnosed cancers. While studies have focused on whether socioeconomic factors contribute to these statistics, researchers have been diligently trying to...

prostate cancer

Widely Cited Prostate-Specific Antigen Screening Publications Influence Biopsy Rates and Associated Complications

While absolute rates of biopsy and postbiopsy complications have decreased following several benchmark prostate-specific antigen (PSA) screening publications, the relative risk for each patient continues to increase, according to a new study by Mayo Clinic researchers. The study is the largest to...

lung cancer

Lung Cancer Incidence and Mortality in Individuals With a Negative Low-Dose CT Prevalence Screen

In an analysis of the National Lung Screening Trial (NLST) cohort reported in The Lancet Oncology, Patz et al found that participants who had a negative low-dose computed tomography (CT) prevalence screen had a low incidence of lung cancer detected at first annual screen and exhibited reduced...

breast cancer

ASCO Endorses Cancer Care Ontario Recommendations on Decision-Making in Adjuvant Systemic Therapy for Early-Stage, Operable Breast Cancer

As reported in the Journal of Clinical Oncology by N. Lynn Henry, MD, PhD, of the University of Michigan Comprehensive Cancer Center, and colleagues, ASCO has endorsed Cancer Care Ontario (CCO) guideline recommendations on the role of patient and disease factors in decisions on adjuvant systemic...

colorectal cancer

Endoscopic Mucosal Resection Is an Alternative to Surgery in Most Patients With Complex Colon Polyps

Using the latest advances in endoscopic resection techniques, more than 75% of patients with complex colon polyps could avoid surgery for their polyp removal, according to new research from The University of Texas MD Anderson Cancer Center. The findings, published by Raju et al in Gastrointestinal ...

issues in oncology

PET Probe [18F]CFA Detects Deoxycytidine Kinase Activity, May Lead to New Ways to Improve Response to Treatment

A promising new discovery by University of California, Los Angeles (UCLA) scientists could lead to a new method of identifying cancer patients whose disease expresses high levels of an enzyme and who are more likely to respond to particular treatments. Their findings were published by Kim et al in...

breast cancer

Therapeutic Combinations May Prevent Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

In preclinical studies, breast cancer cells became resistant to therapeutics targeting CDK4/6, such as palbociclib (Ibrance), in multiple ways. According to the research published by Herrera-Abreu et al in Cancer Research, different combinations of therapeutics might prevent and overcome the...

pancreatic cancer

Meta-analysis of Gene-Expression Datasets Identifies Novel Five-Gene Pancreatic Cancer Classifier

Pancreatic cancer is often diagnosed at a late stage, when curative treatment is no longer possible. A team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) identified and validated an accurate five-gene classifier for discriminating early pancreatic cancer from nonmalignant...

breast cancer

ASCO Guideline on Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy in Women With Early-Stage Invasive Breast Cancer

As reported in the Journal of Clinical Oncology by Harris et al, ASCO released a clinical practice guideline on the use of biomarkers in addition to estrogen receptor/progesterone receptor and HER2 status to guide decisions on adjuvant systemic therapy in women with early-stage invasive breast...

bladder cancer

MRI-Guided Adaptive Reoptimization in Radiotherapy Shows Promise in Urinary Bladder Cancer Treatment

A new radiotherapy technique could help doctors to focus treatment more precisely on tumors in the bladder and reduce damage to surrounding healthy tissue. Researchers showed that pretreatment imaging using magnetic resonance imaging (MRI) was effective at guiding radiotherapy toward tumors in the...

skin cancer

Microneedle Patch Delivers Localized Anti–PD-1 Antibody Immunotherapy to Melanoma in Preclinical Models

Biomedical engineering researchers at North Carolina State University (NC State) and the University of North Carolina at Chapel Hill (UNC Chapel Hill) have developed a technique that uses a patch embedded with microneedles to deliver cancer immunotherapy treatment directly to the site of melanoma....

leukemia

Minimal Residual Disease in AML: Worth Looking?

As summarized in this issue of The ASCO Post, Ivey and colleagues demonstrated that assessing for NPM1-mutated gene transcripts by reverse-transcriptase quantitative polymerase chain reaction assay is a feasible approach for measuring minimal residual disease after acute myeloid leukemia (AML)...

issues in oncology

Quality Improvement Projects Aim at Reducing Errors in Prescribing IV and Oral Chemotherapy

Two quality improvement projects described in the Journal of Oncology Practice resulted in reduced errors in prescribing intravenous (IV) and oral chemotherapy. A project at the University of Texas Medical Branch in Galveston outpatient infusion centers first identified 15 different types of...

colorectal cancer

Patients Diagnosed With Stage I to III Rectal Cancer at Younger Age Have Increased Risk for Positive Lymph Nodes

Patients diagnosed with stage I to III rectal cancer at a younger age are at increased risk of having positive lymph nodes, according to an analysis of data published in the Journal of the National Cancer Institute. “This finding merits further investigation and may ultimately impact treatment...

health-care policy

340B Drug Pricing Program Revisited

I have to disagree with some of the conclusions drawn by Drs. Hagop Kantarjian and Robert Chapman in their editorial on the 340B Drug Pricing Program, which appeared in the January 25 issue of The ASCO Post. Although I’m sure I’m not the best person to provide an alternate view, I do feel strongly...

breast cancer

I Never Forget I Have Cancer

I have a history of fibrocystic breasts, which required biopsies to make certain the cysts were benign, and for years they were. But in 2009, my mammogram screening picked up a suspicious lump in my right breast, which turned out to be stage III estrogen receptor–positive/progesterone...

issues in oncology

Somebody’s Watching You: Meet the Tweet Trackers of the Social Oncology Project

In a one-story concrete industrial building across the street from a lumberyard in Austin, Texas, Greg Matthews and his computers are tracking everything that more than 500,000 U.S.-based physicians post publicly on social media. Every tweet. Every public blog, Facebook, or Instagram post. Every...

Expect Questions and Heightened Interest About Bilateral Mastectomy

Recently released data from the Agency for Healthcare Research and Quality (AHRQ) showed that the rate of mastectomies increased between 2005 and 2013, with much of that increase attributed to bilateral mastectomies among women with early-stage cancer in one breast opting for bilateral...

breast cancer

The Perplexing Increase in Bilateral Mastectomies

The increased rate of bilateral mastectomies, as shown in recently released data from the Agency for Healthcare Research and Quality (AHRQ), is “perplexing,” Ismail Jatoi, MD, PhD, told The ASCO Post. “We are seeing more and more women with unilateral breast cancer opt for bilateral mastectomy,...

survivorship

A Cancer Patient’s Harried Survivorship Story

There are approximately 14 million cancer survivors in the United States, a number that is steadily increasing, thanks to our advances in detection and treatment. However, surviving cancer can leave a host of physical, emotional, and financial hardships for years after diagnosis and treatment. In ...

A Hard Look at the Connection Between Germs and Mental Illness

The relationship between disease and microbes was first proposed in the 17th century, but the basic standards for proving that infection causes disease were not laid down until 1883, when the German bacteriologists Robert Koch and Friedrich Loeffler provided the first evidence of the processes...

Advertisement

Advertisement




Advertisement